printemailclick to share buttonfacebooktwitterlinkedin
Breast Cancer Evidence-based Series (EBS) and Practice Guidelines (PG)
 

Breast cancers encompass ductal carcinoma in situ, non-metastatic and metastatic breast cancer, and pregnancy-associated breast cancer. The titles of the reports produced to date by the DSG are listed below, with links to the PDF versions of those reports. 

The Breast Cancer Disease Site Group (Breast Cancer DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances.

The PEBC has a formal standardized process to ensure the currency of each document. This process guides clinical experts to assess a document’s current status and relevance (please see the PEBC Assessment & Review Protocol for more information). A final status statement is added to the document when this review process is complete. The current status of each guidance document is noted beside the title and link as outlined below:

  • Documents listed as CURRENT are 3 years old or less, up-to-date, and can be used for decision making.
  • Documents listed as IN REVIEW are undergoing assessment for currency and relevance.  The DSG/GDG has determined that it is still appropriate for this document to continue to be available while this updating process unfolds.
  • Documents that are listed as “FOR EDUCATION AND INFORMATION PURPOSES” are documents for which no further updates are planned and whose recommendations may no longer be consistent with recent evidence.  They may be of educational, historical, clinical, or system interest.

If you have any questions regarding a document that is “In Review,” please contact the PEBC ( ccopgi@mcmaster.ca ) or the lead author of the document.

Ductal Carcinoma in Situ

  • Management of Ductal Carcinoma In Situ of the Breast
    1-10 EBS Version 2.2006: September 2006
    Status: IN REVIEW

Non-Metastatic Breast Cancer

  • Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
    Guideline 1-22-A: September 2016
    Status: CURRENT
  • Sentinel Lymph Node Biopsy in Early-stage Breast Cancer
    17-5 EBS: July 2009
    Status: IN REVIEW
    Available on the Surgery Standards page

Locoregional Therapy

  • Locoregional Therapy of Locally Advanced Breast Cancer (LABC)
    1-19 EBS:  September 2014
    Status: CURRENT

Systemic Therapy

  • Optimal Systemic Therapy for Early Female Breast Cancer
    1-21 EBS: September 2014
    Status: CURRENT
  • Both Metastatic Breast Cancer and Non-Metastatic Breast Cancer

    • Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update
      GL-1-A-2016-2
      Status: CURRENT
      This clinical practice guideline is an ASCO-CCO collaboration, produced by a joint expert panel convened by the ASCO Clinical Practice Guidelines Committee and the CCO Program In Evidence-based Care

    For Education and Information Purposes

    • Breast Irradiation in Women with Early-Stage Invasive Breast Cancer Following Breast Conserving Surgery
    • The Role of Taxanes in Neoadjuvant Chemotherapy for Women with Non-Metastatic Breast Cancer
    • The Role of Trastuzumab in Adjuvant and Neoadjuvant Therapy in Women with HER2/neu-Overexpressing Breast Cancer
    • Adjuvant Taxane Therapy for Women with Early-Stage Invasive Breast Cancer
    • Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast Cancer
    • Baseline Staging Tests in Primary Breast Cancer
    • Surgical Management of Early Stage Invasive Breast Cancer
    • The Role of Trastuzumab (Herceptin) in the Treatment of Women with HER2/neu-Overexpressing Metastatic Breast Cancer
    • The Role of Gemcitabine in the Management of Metastatic Breast Cancer
    • Fulvestrant for Systemic Therapy of Locally Advanced or Metastatic Breast Cancer in Postmenopausal Women
    • The Role of the Taxanes in the Management of Metastatic Breast Cancer
    • Vinorelbine in Stage IV Breast Cancer
    • The Role of Aromatase Inhibitors in the Treatment of Postmenopausal Women with Metastatic Breast Cancer
    • Epirubicin, as a Single Agent or in Combination, for Metastatic Breast Cancer
    • Adjuvant Systemic Therapy for Node-Negative Breast Cancer
    • Capecitabine in Stage IV Breast Cancer
    • The Role of HER2/neu in Systemic and Radiation Therapy for Women with Breast Cancer
    • The Role of Aromatase Inhibitors in Adjuvant Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer
    Contact:
    Program in Evidence-Based Care (PEBC)
    McMaster University, Juravinski Site
    G Wing, 2nd Floor
    711 Concession Street
    Hamilton, Ontario, Canada
    L8V 1C3

    Phone: 905.527.4322 ext. 42822
    Fax: 905.526.6775
    Email: ccopgi@mcmaster.ca
Last modified: Mon, Oct 16, 2017
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?

YesNo